The Unseen Ripple Effect: How GLP-1 Drugs Are Quietly Reshaping Our Food, Economy, and Daily Lives

GLP-1 medications like Ozempic and Wegovy are now common enough to show up in the economy. About 1 in 8 US adults say they are taking one, and a large study found that households cut grocery spending by about 5% within six months of starting, with the biggest drops in snacks and sweets and gains in yogurt, fresh fruit and nutrition bars. The effects are real but modest so far, and they shrink over time.
How many people take GLP-1 drugs?
About 12% of US adults. A KFF poll conducted October 27 to November 2, 2025 found that 12% of adults are currently taking a GLP-1 drug for weight loss, diabetes or another condition, and 18% have ever taken one. Cost is a real limit: 56% of users said the drugs were difficult to afford, and 14% of past users said they quit because of the expense.
How do GLP-1 drugs change grocery spending?
They reduce it, especially for calorie-dense foods. A Cornell study published in the Journal of Marketing Research, based on purchase data from about 150,000 households tracked by Numerator, found that households cut grocery spending by an average of 5.3% within six months of starting a GLP-1, and higher-income households by more than 8%.
| Spending fell | Spending rose |
|---|---|
| Savory snacks (about 10%) | Yogurt |
| Sweets, baked goods, cookies | Fresh fruit |
| Some staples such as meat, eggs and bread | Nutrition bars and meat snacks |
The same study found that spending at restaurants softened too, particularly at fast-food chains and coffee shops. Lower food spending lasted at least a year among people who stayed on the drug, though the effect shrank over time.
Why does that matter to food companies?
Because the shift lands hardest on their most profitable categories. A 10% drop in snack spending among a group that is about an eighth of US adults is noticeable for chip, candy and cookie makers, while yogurt, fruit and protein-style snacks gain. That is why food makers are pushing smaller portions and higher-protein products, though the overall effect on national food sales is still much smaller than the headlines sometimes suggest.
Could GLP-1 drugs really save airlines money?
In theory, through lighter passengers burning less fuel. Jefferies analyst Sheila Kahyaoglu estimated that American, Delta, Southwest and United could together save about $580 million a year on fuel as average passenger weight falls. It's an analyst projection based on assumptions about how much weight passengers lose, not a measured saving, so treat it as an illustration of how far the ripple effects can reach.
What does the "GLP-1 economy" mean going forward?
Mostly a gradual shift, not a reset. The measured changes so far are a few percent of grocery spending per user household, concentrated in snacks and fast food, and they depend on people staying on drugs that many find hard to afford. If prices fall and use keeps rising, food, restaurant and even travel businesses will feel more of it; if cost keeps pushing people off the drugs, the shift will stay modest.
